By SmashMeals Editorial — 2026-10-01 — Health & Nutrition
The short answer
CagriSema is an investigational once-weekly fixed-dose combination of cagrilintide, a long-acting amylin analogue, and semaglutide, a GLP-1 receptor agonist. The Phase 3 REDEFINE 1 trial found substantially greater weight loss with CagriSema than placebo, cagrilintide alone or semaglutide alone. It is not currently an FDA-approved obesity treatment.
Key facts
- CagriSema combines cagrilintide 2.4 mg and semaglutide 2.4 mg.
- REDEFINE 1 was a Phase 3 randomized trial in adults with overweight or obesity without diabetes.
- The peer-reviewed results were published in the New England Journal of Medicine in July 2026.
- Gastrointestinal adverse events were common across active treatment groups.
- CagriSema remains investigational.
KINGSPORT, Tenn., Oct. 1, 2026 — The next wave of obesity medicines is not limited to adding more incretin receptors. CagriSema combines semaglutide, a GLP-1 receptor agonist, with cagrilintide, a long-acting amylin analogue. Its Phase 3 REDEFINE 1 results are now peer-reviewed.
CagriSema remains investigational. This article is educational reporting and does not recommend or provide access to the drug.
Why amylin is entering the obesity conversation
Amylin is involved in appetite and meal-related signaling. Cagrilintide is designed as a long-acting amylin analogue. Combining it with semaglutide is intended to target complementary pathways rather than relying on GLP-1 signaling alone.
What REDEFINE 1 found
The Phase 3 trial compared CagriSema with its individual components and placebo in adults with overweight or obesity without diabetes. The combination produced substantially greater average weight loss than placebo and more than either component alone, while gastrointestinal adverse events were common.
What people searching 'CagriSema diet' should know
There is no approved CagriSema diet. The combination itself remains investigational. If future approval occurs, nutrition guidance should be based on the approved label, clinical guidance and individual needs—not assumptions copied from another drug.
For nutrition information relevant to currently approved GLP-1 therapies, use our GLP-1 resource hub.
Commentary, not medical advice
The SmashMeals perspective
CagriSema is important because the obesity-drug market is expanding beyond GLP-1 alone into amylin combinations. For SmashMeals, that means the search taxonomy must expand too—but food claims should remain conservative. There is no validated commercial 'CagriSema meal plan' that makes the investigational drug work better.
Sources & experts referenced
Sources are included for verification. No expert listed here endorses SmashMeals.
- Cagrilintide-Semaglutide in Adults with Overweight or Obesity — New England Journal of Medicine
Why it matters: Primary peer-reviewed Phase 3 REDEFINE 1 publication. - CagriSema obesity development program — Novo Nordisk
Why it matters: Developer description of CagriSema and its investigational status.